A Phase 2 Study of (99m)Tc-tilmanocept in the Detection of Sentinel Lymph Nodes in Melanoma and Breast Cancer

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2011 Feb 19

PMID 21331809

Citations 27

Authors

Stanley P L Leong

Julian Kim

Merrick Ross

Mark Faries

Charles R Scoggins

Wendy L Rich Metz

Frederick O Cope

Richard C Orahood

Affiliations

Soon will be listed here.

Abstract

Background: Several (99m)Tc-labeled agents that are not approved by the U.S. Food and Drug Administration are used for lymphatic mapping. A new low-molecular-weight mannose receptor-based, reticuloendothelial cell-directed, (99m)Tc-labeled lymphatic imaging agent, (99m)Tc-tilmanocept, was used for lymphatic mapping of sentinel lymph nodes (SLNs) from patients with primary breast cancer or melanoma malignancies. This novel molecular species provides the basis for potentially enhanced SLN mapping reliability.

Methods: In a prospectively planned, open-label phase 2 clinical study, (99m)Tc-tilmanocept was injected into breast cancer and cutaneous melanoma patients before intraoperative lymphatic mapping. Injection technique, preoperative lymphoscintigraphy (LS), and intraoperative lymphatic mapping with a handheld gamma detection probe were performed by investigators per standard practice.

Results: Seventy-eight patients underwent (99m)Tc-tilmanocept injection and were evaluated (47 melanoma, 31 breast cancer). For those whom LS was performed (55 patients, 70.5%), a (99m)Tc-tilmanocept hot spot was identified in 94.5% of LS patients before surgery. Intraoperatively, (99m)Tc-tilmanocept identified at least one regional SLN in 75 (96.2%) of 78 patients: 46 (97.9%) of 47 in melanoma and 29 (93.5%) of 31 in breast cancer cases. Tissue specificity of (99m)Tc-tilmanocept for lymph nodes was 100%, displaying 95.1% mapping sensitivity by localizing in 173 of 182 nodes removed during surgery. The overall proportion of (99m)Tc-tilmanocept-identified nodes that contained metastatic disease was 13.7%. Five procedure-related serious adverse events occurred, none related to (99m)Tc-tilmanocept.

Conclusions: Our results demonstrate the safety and efficacy of (99m)Tc-tilmanocept for use in intraoperative lymphatic mapping. The high intraoperative localization and lymph node specificity of (99m)Tc-tilmanocept and the identification of metastatic disease within the nodes suggest SLNs are effectively identified by this novel mannose receptor-targeted molecule.

Citing Articles

A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer.

Jiao D, Chen X, Sun X, Lu Z, Dai H, Wang C BMC Cancer. 2025; 25(1):209.

PMID: 39915736 PMC: 11804033. DOI: 10.1186/s12885-025-13618-x.

Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells.

Chan H, Kuo D, Shueng P, Chuang H Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770505 PMC: 11676442. DOI: 10.3390/ph17121663.

Sentinel Lymph Node Mapping in Lung Cancer: A Pilot Study for the Detection of Micrometastases in Stage I Non-Small Cell Lung Cancer.

Romano G, Zirafa C, Calabro F, Ali G, Manca G, De Liperi A Tomography. 2024; 10(5):761-772.

PMID: 38787018 PMC: 11125324. DOI: 10.3390/tomography10050058.

Macrophage mannose receptor CD206 targeting of fluoride-18 labeled mannosylated dextran: A validation study in mice.

Andriana P, Fair-Makela R, Liljenback H, Karna S, Iqbal I, Makrypidi K Eur J Nucl Med Mol Imaging. 2024; 51(8):2216-2228.

PMID: 38532026 PMC: 11178572. DOI: 10.1007/s00259-024-06686-x.

Tc-Tilmanocept performance for sentinel node mapping in breast cancer, melanoma, and head and neck cancer: a systematic review and meta-analysis from a European expert panel.

Rovera G, de Koster E, Rufini V, Zollino M, Zagaria L, Giammarile F Eur J Nucl Med Mol Imaging. 2023; 50(11):3375-3389.

PMID: 37310426 DOI: 10.1007/s00259-023-06290-5.

References

Ellner S, Mendez J, Vera D, Hoh C, Ashburn W, Wallace A . Sentinel lymph node mapping of the colon and stomach using lymphoseek in a pig model. Ann Surg Oncol. 2004; 11(7):674-81. DOI: 10.1245/ASO.2004.06.007. View

Krag D, Anderson S, Julian T, Brown A, Harlow S, Ashikaga T . Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007; 8(10):881-8. DOI: 10.1016/S1470-2045(07)70278-4. View

Komenaka I, Bauer V, Schnabel F, Horowitz E, Joseph K, Ditkoff B . Allergic reactions to isosulfan blue in sentinel lymph node mapping. Breast J. 2005; 11(1):70-2. DOI: 10.1111/j.1075-122X.2005.21574.x. View

Scherer K, Studer W, Figueiredo V, Bircher A . Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: case report and review of the nomenclature of vital blue dyes. Ann Allergy Asthma Immunol. 2006; 96(3):497-500. DOI: 10.1016/S1081-1206(10)60921-0. View

Ellner S, Hoh C, Vera D, Darrah D, Schulteis G, Wallace A . Dose-dependent biodistribution of [(99m)Tc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping. Nucl Med Biol. 2003; 30(8):805-10. DOI: 10.1016/j.nucmedbio.2003.10.001. View

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

Wallace A, Hoh C, Limmer K, Darrah D, Schulteis G, Vera D . Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol. Nucl Med Biol. 2009; 36(6):687-92. PMC: 4201841. DOI: 10.1016/j.nucmedbio.2009.04.007. View

Cipra T, Fuchs A, Formanek J, Kubat J, MIKISKOVA H, Zajicek P . Detection and interpolation of outliers in biosignals. Act Nerv Super (Praha). 1990; 32(4):283-91. View

Stojadinovic A, Peoples G, Jurgens J, Howard R, Schuyler B, Kwon K . Standard versus pH-adjusted and lidocaine supplemented radiocolloid for patients undergoing sentinel-lymph-node mapping and biopsy for early breast cancer (PASSION-P trial): a double-blind, randomised controlled trial. Lancet Oncol. 2009; 10(9):849-54. DOI: 10.1016/S1470-2045(09)70194-9. View

10.

Leong S, Donegan E, Heffernon W, Dean S, Katz J . Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000; 7(5):361-6. DOI: 10.1007/s10434-000-0361-x. View

11.

Hoh C, Wallace A, Vera D . Preclinical studies of [(99m)Tc]DTPA-mannosyl-dextran . Nucl Med Biol. 2003; 30(5):457-64. DOI: 10.1016/s0969-8051(03)00028-3. View

12.

Wallace A, Hoh C, Ellner S, Darrah D, Schulteis G, Vera D . Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2006; 14(2):913-21. DOI: 10.1245/s10434-006-9099-4. View

13.

Mariani G, Gipponi M, Moresco L, Villa G, Bartolomei M, Mazzarol G . Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. J Nucl Med. 2002; 43(6):811-27. View

14.

Krynyckyi B, Kim C, Goyenechea M, Chan P, Zhang Z, Machac J . Clinical breast lymphoscintigraphy: optimal techniques for performing studies, image atlas, and analysis of images. Radiographics. 2004; 24(1):121-45. DOI: 10.1148/rg.241025713. View

15.

Wallace A, Hoh C, Vera D, Darrah D, Schulteis G . Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003; 10(5):531-8. DOI: 10.1245/aso.2003.07.012. View

16.

Ferlay J, Parkin D, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46(4):765-81. DOI: 10.1016/j.ejca.2009.12.014. View

17.

Wallace A, Hoh C, Darrah D, Schulteis G, Vera D . Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol. 2007; 34(7):849-53. PMC: 4189800. DOI: 10.1016/j.nucmedbio.2007.05.003. View

18.

King T, Fey J, Van Zee K, Heerdt A, Gemignani M, Port E . A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer. Ann Surg Oncol. 2004; 11(5):535-41. DOI: 10.1245/ASO.2004.10.014. View

19.

Morton D, Thompson J, Cochran A, Mozzillo N, Elashoff R, Essner R . Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006; 355(13):1307-17. DOI: 10.1056/NEJMoa060992. View

20.

Wallace A, Ellner S, Mendez J, Hoh C, Salem C, Bosch C . Minimally invasive sentinel lymph node mapping of the pig colon with Lymphoseek. Surgery. 2006; 139(2):217-23. DOI: 10.1016/j.surg.2005.06.038. View